REFERENCES
1. Lassaletta A, Guerreiro Stucklin A, Ramaswamy V, et al. Profound
clinical and radiological response to BRAF inhibition in a 2-month-old
diencephalic child with hypothalamic/chiasmatic glioma. Pediatr
Blood Cancer . Nov 2016;63(11):2038-41. doi:10.1002/pbc.26086
2. Chiu B, Chan J, Das S, Alshamma Z, Sergi C. Pediatric Sarcoidosis: A
Review with Emphasis on Early Onset and High-Risk Sarcoidosis and
Diagnostic Challenges. Diagnostics (Basel) . Oct 25
2019;9(4)doi:10.3390/diagnostics9040160
3. Huh JY, Moon DS, Song JW. Sarcoid-like reaction in patients with
malignant tumors: Long-term clinical course and outcomes. Front
Med (Lausanne) . 2022;9:884386. doi:10.3389/fmed.2022.884386
4. Beijer E, Roodenburg-Benschop C, Schimmelpennink MC, Grutters JC,
Meek B, Veltkamp M. Elevated Serum Amyloid a Levels Are not Specific for
Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype.Cells . Mar 7 2021;10(3)doi:10.3390/cells10030585
5. Ascierto PA, Dummer R. Immunological effects of BRAF+MEK inhibition.Oncoimmunology . 2018;7(9):e1468955.
doi:10.1080/2162402X.2018.1468955
6. Baumann D, Hagele T, Mochayedi J, et al. Proimmunogenic impact of MEK
inhibition synergizes with agonist anti-CD40 immunostimulatory
antibodies in tumor therapy. Nat Commun . May 1 2020;11(1):2176.
doi:10.1038/s41467-020-15979-2
7. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of
Sarcoidosis. An Official American Thoracic Society Clinical Practice
Guideline. Am J Respir Crit Care Med . Apr 15 2020;201(8):e26-e51.
doi:10.1164/rccm.202002-0251ST
8. Anastasopoulou A, Diamantopoulos PT, Skalioti C, et al. The diagnosis
and management of sarcoid-like reactions in patients with melanoma
treated with BRAF and MEK inhibitors. A case series and review of the
literature. Ther Adv Med Oncol . 2021;13:17588359211047349.
doi:10.1177/17588359211047349
9. Bala VM, Mitsogianni M, Laschos K, et al. Mediastinal and hilar
sarcoid-like reaction in a patient treated with dabrafenib and
trametinib for metastatic melanoma: A case report and review of the
literature. Mol Clin Oncol . May 2022;16(5):99.
doi:10.3892/mco.2022.2532
10. Dando EE, Rosenbach M, English III JC. Granulomatous drug reactions
from targeted therapeutics. Medical Research Archives . 2020-06-18
2020;8(6)doi:10.18103/mra.v8i6.2138
11. Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous
granulomatous eruption and successful response to potent topical
steroids in patients undergoing targeted BRAF inhibitor treatment for
metastatic melanoma. JAMA Dermatol . Mar 2014;150(3):307-11.
doi:10.1001/jamadermatol.2013.7919
12. van Moorsel CH, Christiani DC. Genetic susceptibility to
sarcoidosis, a chronic inflammatory disorder. Am J Respir Crit
Care Med . Nov 1 2012;186(9):816-8. doi:10.1164/rccm.201209-1582ED
13. Calender A, Weichhart T, Valeyre D, Pacheco Y. Current Insights in
Genetics of Sarcoidosis: Functional and Clinical Impacts. J Clin
Med . Aug 13 2020;9(8)doi:10.3390/jcm9082633
14. Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory
syndromes: state of the art on genetic, clinical, and therapeutic
issues. Int J Rheumatol . 2013;2013:513782.
doi:10.1155/2013/513782
15. Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L.
Autoinflammatory granulomatous diseases: from Blau syndrome and
early-onset sarcoidosis to NOD2-mediated disease and Crohn’s disease.RMD Open . 2015;1(1):e000097. doi:10.1136/rmdopen-2015-000097
16. Tsao YP, Tseng FY, Chao CW, et al. NLRP12 is an innate immune
checkpoint for repressing IFN signatures and attenuating lupus nephritis
progression. The Journal of clinical investigation . Feb 1
2023;133(3)doi:10.1172/jci157272
17. Nobre L, Zapotocky M, Ramaswamy V, et al. Outcomes of BRAF V600E
Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO
Precis Oncol . 2020;4doi:10.1200/PO.19.00298